301207 华兰疫苗
2026/09 - 九个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入300,887-62.67%1,202,5061,127,8122,410,4281,825,641
减:营业总成本410,741-45.78%1,021,513961,2841,407,1731,135,563
    其中:营业成本112,373-39.40%266,941212,559287,098217,451
               财务费用(1,477)48.51%(1,768)(7,064)(5,022)(5,476)
               资产减值损失13,1066.75%(58,208)(74,225)(94,919)(151,738)
公允价值变动收益9,853-34.80%12,72624,30139,67716,848
投资收益46,561-16.11%76,80776,07370,49155,597
    其中:对联营企业和合营企业的投资收益------------
营业利润(18,136)-113.01%189,776214,8561,010,057592,634
利润总额(18,329)-113.32%187,786214,5461,006,881589,479
减:所得税费用(13,878)-360.90%4,8669,030146,91369,844
净利润(4,451)-103.36%182,920205,515859,969519,635
减:非控股权益------------
股东净利润(4,451)-103.36%182,920205,515859,969519,635

市场价值指针
每股收益 (元) *-0.008-103.37%0.3070.3441.4320.881
每股派息 (元) *0.100-83.33%1.4000.2000.6000.300
每股净资产 (元) *8.593-9.00%9.49110.00510.43813.741
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容